Index
General description
The AGE Reader provides an immediate cardiovascular risk prediction for major chronic diseases, such as diabetes, cardiovascular disease and renal failure. The AGE Reader yields a real time and non-invasive assessment of cardiovascular risk. The method is convenient, easy to use and validated. The AGE Reader measures tissue accumulation of Advanced Glycation Endproducts (AGEs) by means of fluorescence techniques (skin autofluorescence (skin AF)). AGEs play a key role in the pathogenesis of many age-related diseases, such as diabetes, cardiovascular disease and renal failure.
Technology
The AGE Reader has a light source which illuminates the skin of the forearm. This light will excite fluorescent moieties in the tissue which will emit light of a different wavelength. In the used wavelength band the major contribution in fluorescence comes from fluorescent AGEs linked mostly to collagen, but also to other proteins and lipids. The emitted light is detected using a spectrometer.
By using specific technical adaptations including selection of specific wavelength, modulated or pulsed light sources, a more selective discrimination of specific AGEs is obtained.
Read more about the technology on the page with information for professionals.
Clinical validation
The comfortable and safe AGE Reader measurement offers crucial clinical information to clinicians and researchers. The AGE Reader has been validated against the gold standard for measuring AGEs (skin biopsies). It was shown that skin AF is strongly correlated with AGEs.
The device has been clinically validated in multiple large-scale, clinical trials over the last few years involving tens of thousands of healthy controls, diabetics, cardiovascular and renal patients. The clinical studies demonstrate that skin autofluorescence is a strong and independent risk predictor for mortality and cardiovascular events. In particular, it can independently predict cardiovascular co-morbidity and mortality in diabetes, renal failure and dialysis patients.
If you want to read more about the clinical validation of the AGE Reader, please visit the page with information for professionals.
Read more about the clinical validation on the page with information for professionals.
Clinical Value
The information from the AGE Reader can assist physicians in focusing treatment on patients with the highest risk of complications. This includes patients suffering from diabetes mellitus, renal failure but also acute disorders like acute coronary syndromes and sepsis. Moreover it is an excellent tool for researchers in various fields.
AGE Reader applications
| Patient management |
|
| Clinical studies |
|
| Treatment selection and monitoring |
|
|
Scientific research |
|
|
New drug development |
|
|
Public screening |
|
Downloads
Find a distributor in your country. If your country is not listed, please contact DiagnOptics for your enquiries: sales@diagnoptics.com
The AGE Reader CU is the latest model in the AGE Reader series. This compact device features a built-in mini computer and battery and is operated through a touch screen panel. The AGE Reader CU is mobile and requires no setup. After the measurement, a direct printout of the report can be made by using a pre-selected printer. Optional pc software to perform further analysis on the data is available (AGE Reader CU Dataview).
The AGE Reader SU is the classic model. The measurement device is connected to a pc or laptop and is controlled by the AGE Reader software. It allows users to process and analyze the data immediately on the external computer. A printout of the measurement report can be made. It is particularly suitable for users who wish to do immediate analysis on their measurement results.
